Proton pump inhibitors and risk of gastric cancer: A population-based cohort study

British Journal of Cancer

Volumn 100, Issue 9, 2009, Pages 1503-1507

  Poulsen, A H ^a   Christensen, S ^b   McLaughlin, J K ^c,d   Thomsen, R W ^b   Sorensen H T ^b   Olsen, J H ^a   Friis, S ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cohort study; Histamine 2 antagonists; Proton pump inhibitors; Risk; Stomach neoplasms

Indexed keywords

AMOXICILLIN; CIMETIDINE; CLARITHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; METRONIDAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CLINICAL EVALUATION; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG USE; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTROSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; STOMACH CANCER; ADENOCARCINOMA; COHORT ANALYSIS; MIDDLE AGED; REPRODUCIBILITY; RISK FACTOR; STATISTICS; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; COHORT STUDIES; DENMARK; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS; PROTON PUMP INHIBITORS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 65549096192     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605024     Document Type: Article

References (41)

1. Chow W (1999) Human cancer. Int J Cancer 81: 871-876
2. Dua K, Bardan E, Ren J, Sui Z, Shaker R (1998) Effect of chronic and acute cigarette smoking on the pharyngo-upper oesophageal sphincter contractile reflex and reflexive pharyngeal swallow. Gut 43: 537-541
3. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, Schatzkin A (2007) A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 165: 1424-1433
4. Hirayama T (1984) Cancer mortality in nonsmoking women with smoking husbands based on a large-scale cohort study in Japan. Prev Med 13: 680-690
5. IARC (2004) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to human. In Tobacco Smoke and Involuntary Smoking. Volumes 83. Lyon, France
6. Jee SH, Ohrr H, Kim IS (1999) Effects of husbands' smoking on the incidence of lung cancer in Korean women. Int J Epidemiol 28: 824-828
7. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, Lunet N (2008) Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 19: 689-701
8. Ma L, Wang HY, Chow JY, Cho CH (1999) Cigarette smoke increases apoptosis in the gastric mucosa: role of epidermal growth factor. Digestion 60: 461-468
9. Mao Y, Hu J, Semenciw R, White K (2002) Active and passive smoking and the risk of stomach cancer, by subsite, in Canada. Eur J Cancer Prev 11: 27-38
10. Nishino Y, Tsubono Y, Tsuji I, Komatsu S, Kanemura S, Nakatsuka H, Fukao A, Satoh H, Hisamichi S (2001) Passive smoking at home and cancer risk: a population-based prospective study in Japanese nonsmoking women. Cancer Causes Control 12: 797-802
11. Pandolfino JE, Kahrilas PJ (2000) Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 12: 837-842
12. Sandler DP, Comstock GW, Helsing KJ, Shore DL (1989) Deaths from all causes in non-smokers who lived with smokers. Am J Public Health 79: 163-167
13. Shin VY, Cho CH (2005) Nicotine and gastric cancer. Alcohol 35: 259-264
14. Wang H, Ma L, Li Y, Cho CH (2000) Exposure to cigarette smoke increases apoptosis in the rat gastric mucosa through a reactive oxygen speciesmediated and p53-independent pathway. Free Radic Biol Med 28: 1125-1131
15. Wu AH, Wan P, Bernstein L (2001) A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12: 721-732
16. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH (1999) The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 46: 263-268
17. Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, Murphy M, Paterson KR, Rowsell R, Thomas S, Vessey M (2003) Mortality study of 18000 patients treated with omeprazole. Gut 52: 942-946
18. Danish Board of Health (1989, 1995) Danish Classification of Surgical Procedures and Therapies. Danish Board of Health: Copenhagen
19. Eissele R, Brunner G, Simon B, Solcia E, Arnold R (1997) Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 112: 707-717
20. Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44: 445-448
21. Garcia Rodriguez LA, Lagergren J, Lindblad M (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55: 1538-1544
22. Gillen D, McCoIl KE (2001) Problems associated with the clinical use of proton pump inhibitors. Pharmacol Toxicol 89: 281-286
23. Havu N (1986) Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35(Suppl 1): 42-55
24. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Luckers A, Dekkers CP, Havu N, Meuwissen SG (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121: 161-167
25. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A, Group LT (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661-669
26. Kuipers EJ (2006) Proton pump inhibitors and gastric neoplasia. Gut 55: 1217-1221
27. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG (1996) Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334: 1018-1022
28. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2000) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14: 651-668
29. Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G (1988) Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 39: 126-135
30. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E (1993) Longterm omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 104: 1356-1370
31. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers E (2006) Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 56: 772-781
32. McColl KE (2006) Acid inhibitory medication and risk of gastric and oesophageal cancer. Gut 55: 1532-1533
33. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: 915-920
34. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sorensen HT (2007) Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133: 755-760
35. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 44: 535-539
36. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789
37. van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ (2008) Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 103: 966-973
38. Waldum HL, Gustafsson B, Fossmark R, Qvigstad G (2005) Antiulcer drugs and gastric cancer. Dig Dis Sci 50(Suppl 1): S39-S44
39. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC (2003) Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 95: 1784-1791
40. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133: 748-754
41. Ye W, Nyren O (2003) Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia Gut 52: 938-941